오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - methylphenidate hydrochloride, quantity: 10 mg - tablet, uncoated - excipient ingredients: calcium phosphate; magnesium stearate; gelatin; purified talc; wheat starch; lactose monohydrate - ritalin 10 tablets and ritalin la capsules are indicated for the treatment of adhd. ritalin 10 tablets are also indicated for the treatment of narcolepsy. attention-deficit hyperactivity disorder (adhd) adhd was previously known as attention-deficit disorder. other terms used to describe this behavioural syndrome include: minimal brain dysfunction in children, hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction and psycho-organic syndrome of children. ritalin 10 / ritalin la are indicatedas an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. special diagnostic considerations for adhd in children: the aetiology of this syndrome is unknown and there is no single diagnostic test.

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

vetoquinol sa - febantel; pyrantel embonate ; praziquantel - tablet - 150,144,50 mg/tablet - febantel, combinations

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

vetoquinol sa - febantel; pyrantel embonate ; praziquantel - tablet - 150,144,50 mg/tablet - febantel, combinations

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

vetoquinol sa - febantel; pyrantel embonate ; praziquantel - tablet - 150,144,50 mg/tablet - febantel, combinations

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

vetoquinol sa - febantel; pyrantel embonate ; praziquantel - tablet - 150,144,50 mg/tablet - febantel, combinations

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ethinylestradiol, quantity: 30 microgram; levonorgestrel, quantity: 150 microgram - tablet, film coated - excipient ingredients: povidone; magnesium stearate; lactose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - oral contraception.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; lactose monohydrate; colloidal anhydrous silica; magnesium stearate - women:moderately severe to severe signs of androgenization. moderately severe/severe forms of hirsutism. moderately severe/severe androgen-dependent loss of scalp hair (moderately severe/severe androgenic alopecia).moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenization.cyproterone acetate inhibits the influence of male sex hormones which are also produced by the female. it is thus possible to treat diseases in women caused either by increased production of androgens or a particular sensitivity to these hormones hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment.if cyprostat 50mg is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of childbearing potential, pregnancy must be excluded at the commencement of treatment and ethinyloestradiol taken as well to ensure contraception. this also promotes regular menstruation men:reduction o

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - acetazolamide, quantity: 250 mg - tablet, uncoated - excipient ingredients: maize starch; calcium hydrogen phosphate dihydrate; magnesium stearate; povidone; sodium starch glycollate - for adjunctive treatment of oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalised seizures); chronic simple (open angle) glaucoma, secondary glaucoma and preoperatively in acute angle closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 1148 mg (equivalent: amoxicillin, qty 1000 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; purified talc; microcrystalline cellulose; hypromellose; titanium dioxide; povidone; magnesium stearate - for the treatment of acute exacerbation of chronic bronchitis.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 1004.31 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; sodium starch glycollate; dichloromethane; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amoxyclav b&b 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis.,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infections.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.